

REMARKS

The claims are 22-31, with claim 22 being the sole independent claim. Claim 22 is directed to triazole compounds of Formula (I) and (IA) wherein X is S, R¹ is optionally substituted furan-C₁alkyl, R² is optionally substituted Ar-C₀₋₆alkyl, and R³ is H, optionally substituted C₁₋₆ alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl. Claims 1-21 have been cancelled without prejudice or disclaimer. Support for new claims 22-31 may be found original claims 1-21. Additional support for claim 31 may be found in the specification at page 97, line 28 to page 11, line 24. No new matter has been added.

A substitute specification is being submitted herewith to correct obvious errors in the originally filed specification. A marked-up copy thereof (where the changes are highlighted in bold text) is also enclosed. In particular, several heterocycle-containing compounds were named so as not to include a methyl (methylene, -CH₂-) group linking the heterocycle to the central triazole ring. More specifically compounds containing the name fragment furan-2-ylthio, furan-3-ylthio, thienyl-2-ylthio, thienyl-3-ylthio, and quinolin-8-ylthio have been renamed to recite the fragment as furan-2-ylmethylthio, furan-3-ylmethylthio, thienyl-2-ylmethylthio, thienyl-3-ylmethylthio, and quinolin-8-ylmethylthio. Also changed was the name of the compound of Example 24: 4-(5-anilino-2 H-[1,2,4]triazol-3-yl thio)-benzoic acid was renamed as 4-(5-anilino-2 H-[1,2,4]triazol-3-yl thiomethyl)-benzoic acid. In all occurrences where such changes have occurred, the starting materials used in the preparation of these compounds contained a linking methyl (methylene) group moiety, for example, 2- or 3-chloromethyl-thiophene, 2- or 3-chloromethyl-furan, 8-bromomethylquinoline or 4-(chloromethyl)benzoic acid.


Applicants respectfully submit that one of ordinary skill in the art would understand that, based on the synthetic method of preparation and the starting materials as described in the subject specification, the compounds of this invention should contain a methyl/methylene linking group, would recognize that the names provided for such compounds in the originally filed specification were in error and would understand what the names of the compounds should be. Applicants respectfully submit that the renaming of these compounds (all occurrences) does not constitute new matter. (M.P.E.P. 2163.07 and *In re Oda*, 170 U.S.P.Q. 268 (CCPA 1971))

Applicants respectfully submit that the subject application is in condition for allowance. If the Examiner has any objections or concerns, the Examiner is respectfully requested to contact Applicants' undersigned attorney to resolve such issues and advance the case to issue.

This Amendment is being filed together with Petition for Extension of Time and a Request for Continued Examination. In the event that these papers get separated or there is any deficiency in the Petition, this constitutes a Petition for Extension of Time for the

minimum period of time required to effect timely filing of this Amendment, together with authorization to charge any fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper to Deposit Account No. 19-2570.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Kathryn L. Sieburth', written in a cursive style.

Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property-UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-5012
Facsimile: (610) 270-5090
N:\kls\cases\p51034\Response 11-14-03.doc